Back to Journals » Drug Design, Development and Therapy » Volume 9

Combination therapy of ursodeoxycholic acid and budesonide for PBC–AIH overlap syndrome: a meta-analysis

Authors Zhang H, Yang J, Zhu R, Zheng Y, Zhou Y, Dai W, Wang F, Chen K, Li J, Wang C, Li S, Liu T, Abudumijiti H, Zhou Z, Wang J, Lu W, Wang J, Xia Y, Zhou Y, Lu J, Guo C

Received 18 September 2014

Accepted for publication 1 November 2014

Published 17 January 2015 Volume 2015:9 Pages 567—574

DOI https://doi.org/10.2147/DDDT.S74515

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Shu-Feng Zhou


Huawei Zhang,1,2,* Jing Yang,1,* Rong Zhu,1,3 Yuanyuan Zheng,1 Yuqing Zhou,1,2 Weiqi Dai,1 Fan Wang,1 Kan Chen,1 Jingjing Li,1 Chengfen Wang,1 Sainan Li,1 Tong Liu,1 Huerxidan Abudumijiti,1 Zheng Zhou,1,3 Jianrong Wang,1,3 Wenxia Lu,1,3 Junshan Wang,1 Yujing Xia,1 Yingqun Zhou,1 Jie Lu,1 Chuanyong Guo1

1Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, 2The First Affiliated Hospital of Soochow University, Suzhou, 3The First Clinical Medical College of Nanjing Medical University, Nanjing, People’s Republic of China

*These authors contributed equally to this work and should be considered co-first authors

Abstract: In this study, a meta-analysis of randomized controlled trials comparing ursodeoxycholic acid (UDCA) monotherapy with combination therapies utilizing UDCA and budesonide was performed. We found that combination therapy with UDCA and budesonide was more effective than UDCA monotherapy for primary biliary cirrhosis–autoimmune hepatitis overlap syndrome. Moreover, compared to prednisone, budesonide has fewer side effects.

Keywords: meta-analysis, UDCA, budesonide, combination therapy, PBC–AIH overlap syndrome

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]